In yet another sign of the vigorous growth of the vaccine business, GlaxoSmithKline has announced plans to invest $190 million in a new vaccine plant to be built in Singapore. The new plant will be GSK's largest outside of Belgium and is expected to open in 2010 with more than 200 workers. This is a major win for Singapore, where the government has been actively supporting the biopharma industry. A variety of big pharma and small biotech companies have set up operations there. Economic development officials say that another vaccine plant announcement is expected later this year and GSK has made it clear that it intends to continue to expand its presence in the city-state.
- here's the AFX report [1] on the GSK plant
Links:
[1] http://www.forbes.com/business/feeds/afx/2006/06/08/afx2801583.html